Wach, J.; Güresir, Á.; Hamed, M.; Vatter, H.; Herrlinger, U.; Güresir, E.
Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma. Cancers 2022, 14, 2134.
https://doi.org/10.3390/cancers14092134
AMA Style
Wach J, Güresir Á, Hamed M, Vatter H, Herrlinger U, Güresir E.
Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma. Cancers. 2022; 14(9):2134.
https://doi.org/10.3390/cancers14092134
Chicago/Turabian Style
Wach, Johannes, Ági Güresir, Motaz Hamed, Hartmut Vatter, Ulrich Herrlinger, and Erdem Güresir.
2022. "Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma" Cancers 14, no. 9: 2134.
https://doi.org/10.3390/cancers14092134
APA Style
Wach, J., Güresir, Á., Hamed, M., Vatter, H., Herrlinger, U., & Güresir, E.
(2022). Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma. Cancers, 14(9), 2134.
https://doi.org/10.3390/cancers14092134